Spinraza India – Price, Approval, Use For SMA, Dosage & More

Sprinraza is a revolutionary drug for treating Spinal Muscular Atrophy (SMA), a debilitating genetic condition. This complete guide will provide an in-depth look into Sprinraza, including its cost, uses, potential side effects, and other vital information. SMA is a rare but severe disorder that affects the ability of the body to control movement, leading to muscle weakness and difficulty walking and breathing. Because of this, patients must receive the best possible treatment, and this guide will help explain why Sprinraza is a viable option. 

It will also explain the Spinraza price in India, including how it is priced so high, what resources are available to help cover the cost of treatment, its potential side effects, and the best ways to monitor its use. By the end of this guide, readers should better understand Sprinraza and how to access affordable treatment.

What’s The Spinraza Price In India?

A one-time dose of Spinraza injection in India costs approximately Rs 87 lakhs. Spinraza is a biologic medicine used to treat Spinal Muscular Atrophy (SMA), a rare genetic disease affecting the nerves responsible for controlling muscle movement. It is administered as an injection, directly into the spinal canal, under general anesthesia. 

The cost of a one-time dose of Spinraza injection in India is based on several factors, such as the patient’s weight, diagnosis, and age. The injection cost also depends on the required doses and the hospital where the procedure is being done. Some insurance companies may cover the cost of Spinraza injection in India. It is essential to check with your insurance provider before undergoing the treatment.

The cost of Spinraza treatment in India is relatively high because it is relatively new and expensive. However, the cost of Spinraza in India is still much lower than in other countries, where it can cost up to $750,000 for the entire treatment. The cost of Spinraza in India will likely decrease as more people become aware of the treatment and demand for it increases. However, it is currently the only available treatment for SMA and will likely remain so for some time.

Why Spinraza’s Price Is So High In India?

Spinraza is a drug used to treat spinal muscular atrophy (SMA), a rare genetic disorder affecting muscles and nerves. Biogen, a US-based biotechnology company, produces the drug. In India, the cost of Spinraza is exceptionally high, making it inaccessible to many people. The high cost of the drug is due to several factors.

• Firstly, Spinraza is a rare drug, and the production and distribution of this drug are limited. Biogen can charge a higher price for the drug due to its rarity and limited availability. 

• Secondly, the cost of importing and distributing the drug in India is higher than in other countries due to the country’s complex customs regulations and high taxes. This adds to the cost of the drug. 

• Thirdly, the Indian government has imposed price caps on some drugs, including Spinraza, to make them more affordable. However, this price cap is not enough to make the drug affordable for everyone. 

• Finally, Biogen charges a higher price for the drug in India due to the country’s large population and high demand for the drug. This allows the company to profit more from selling the drug in India. 

Overall, the high cost of Spinraza in India is due to several factors, including its rarity, the cost of importing and distributing the drug, government price caps, and the high demand for the drug.

Is Spinraza Approved In India?

No, Spinraza is not approved in India. It is approved in the United States, Canada, the European Union, Australia, and several other countries but not approved for sale in India. However, Spinraza can be imported by consulting the physician about this option and finally getting government approval for access to unapproved medications. 

In India, Evrysdi (Risdiplam), produced by Roche, is the only drug approved for SMA treatment in India. 

Uses Of Spinraza

Spinraza (nusinersen) is a medication used to treat spinal muscular atrophy (SMA). SMA is a genetic disorder that affects muscle strength and movement, typically causing progressive muscle weakness and wasting. Spinraza works by increasing the amount of functional SMN protein in the body. SMN protein is essential for the proper functioning of the muscles, and its absence or shortage can lead to SMA.

Spinraza is a type of antisense oligonucleotide (ASO), which is an RNA-targeting drug. It is injected directly into the spinal fluid and works by binding to a specific area of the SMN2 gene, thereby increasing the production of the SMN protein. This increased production of SMN protein helps to improve muscle function in people with SMA.

Spinraza is used to treat all types of SMA, including Type 1 (infantile-onset), Type 2 (intermediate-onset), and Type 3 (juvenile-onset). It is also used to treat some Type 4 (adult-onset) SMA cases. It is typically prescribed as a monthly injection for as long as it is effective.

Spinraza has been proven to improve muscle strength and function in people with SMA and to slow disease progression. It also helps people with SMA walk farther and better hold their heads. Additionally, Spinraza has been shown to reduce the risk of complications associated with SMA, such as respiratory failure, and improve the quality of life.

What Are The Side Effects Of Spinraza Drug On Patients?

Spinraza (nusinersen) is a drug used to treat spinal muscular atrophy (SMA), a rare genetic disorder that affects muscle strength, breathing, and movement. The most common side effects of Spinraza include injection site reactions, upper respiratory tract infections, constipation, headache, and nausea.

• Injection site reactions are the most commonly reported side effect of Spinraza. These reactions can include redness, swelling, bruising, itching, pain, and irritation at the injection site. It is essential to contact a healthcare provider if these reactions become severe or persist.

• Upper respiratory tract infections, including sinus infections, are another common side effect of Spinraza. These infections usually result in a sore throat, fever, congestion, and coughing. It is essential to contact a healthcare provider if these symptoms become severe or persist.
• Constipation is another commonly reported side effect of Spinraza. Drinking enough fluids and increasing dietary fiber intake is vital to prevent or alleviate this side effect.

• Headache and nausea are also common side effects of Spinraza. Contacting a healthcare provider if these side effects become severe is important.

• Less common side effects of Spinraza include throat pain, fatigue, abdominal pain, vomiting, and diarrhea.

• In rare cases, Spinraza has been associated with severe side effects, including liver damage, kidney failure, respiratory failure, and death. Contacting a healthcare provider immediately if these side effects occur is essential.

Which SMA Treatment Is More Effective- Spinraza Or Zolgensma?

Spinraza (nusinersen) is a medication used to treat spinal muscular atrophy (SMA), a genetic condition that affects muscle movement and strength. It increases the production of (SMN) protein essential for normal muscle function. Spinraza is injected directly into the spinal fluid and is given every four months.

Zolgensma (onasemnogene abeparvovec) is a gene therapy used to treat SMA. It delivers a functional SMN1 gene directly to the cells, restoring the body’s average production of SMN protein. Is zolgensma approved in india? Zolgensma is administered as a one-time intravenous infusion.

Both Spinraza and Zolgensma are effective treatments for SMA, but the most effective treatment may depend on the individual and their specific needs.

Studies have shown that Spinraza can improve motor function in children with SMA, but its effects may not be permanent and regular dosing is required. The effects of Zolgensma may be more long-lasting, as gene therapy works by restoring the body’s ability to produce the SMN protein. Spinraza is more expensive than Zolgensma, but onasemnogene zolgensma price in india may be less cost-effective in the long term as it is a one-time treatment.

Overall, both Spinraza and Zolgensma can be effective treatments for SMA, and the best treatment for an individual should be determined on a case-by-case basis. Consultation with a medical professional is recommended to determine which treatment is best for a particular person.

Is Spinraza Available In India?

Spinraza has yet to be available in India. Spinraza is an FDA-approved treatment for spinal muscular atrophy (SMA), a rare genetic disease. It is produced by the US-based biotechnology company Biogen and is currently approved for use in the US, Canada, Europe, and Japan. 

In India, there are currently no approved treatments for SMA. However, the ICMR (Indian Council of Medical Research) and the Department of Biotechnology (DBT) have worked together to develop a treatment for SMA and related neuromuscular diseases.

The only viable option for people with SMA in India is to get the drug through an international drug procurement platform. This method allows patients to receive the drug from the US, Canada, Europe, or Japan. A doctor must prescribe the drug, and the patient must obtain the appropriate documents before it can be shipped to India.

In addition, there are some non-profit organizations that provide free access to Spinraza in India. These organizations work with the ICMR and the DBT to provide access to the drug. These organizations may provide access to Spinraza through their network of doctors, pharmacies, and other healthcare providers.

Lastly, some private hospitals in India can also provide access to Spinraza. These private hospitals may be able to purchase the drug directly from Biogen or through a local distributor. It is vital to note that the cost of the Spinraza may be significantly higher in India than in other countries.

How Is Spinraza Taken?

Spinraza (nusinersen) is an injection administered directly into the fluid that surrounds the spinal cord. It is given in three loading doses and then maintenance doses, usually every four months. 

• The first loading dose is given as four injections into the fluid surrounding the spinal cord (intrathecal space). It is given in four different sites, which are the same for each injection. The injections are given under the guidance of a radiologist or other specialist using X-ray or ultrasound technology.

• The second and third loading doses are given two and four months after the first injection. Each of these doses is given as two injections into the intrathecal space. 

• Maintenance doses are given every four months after the third loading dose. These are single injections into the intrathecal space. 

During each injection, the patient should be monitored for any signs or symptoms of an allergic reaction. Patients should also be monitored for any changes in their neurological condition for at least one hour after each injection. Spinraza is typically administered in a doctor’s office or hospital, and patients may need to stay in the hospital for observation after the injection. Patients are advised to take precautions to prevent infection at the injection site, such as washing their hands before and after the injection and avoiding touching it. 

Patients should also talk to their doctor about other medications, as Spinraza may interact with certain medications. Patients should also discuss other medical conditions, as Spinraza may not be appropriate for some patients. 

Preventive Measures To Be Taken Before And After Consuming Spinraza

Before Taking Spinraza (Nusinersen)

1. Before taking a Spinraza injection, you must discuss with your doctor all of your medical history, including any recent illnesses or surgeries. You should also inform your doctor of any medications or supplements that you take, including herbal supplements, vitamins, or over-the-counter drugs.

2. It is important to tell your doctor if you are pregnant or breastfeeding. Spinraza is not recommended for use in pregnant women and is not known to be safe during pregnancy.

3. Before taking a Spinraza injection, you should also inform your doctor of any allergies, including allergies to any medications.

4. Your doctor may recommend getting a physical examination and blood tests before taking a Spinraza injection. This is to ensure you are healthy enough to receive the injection.

5. Your doctor may also recommend having an electrocardiogram (ECG) before taking the injection. This is to make sure that your heart is healthy enough to receive the injection.

6. Your doctor will also advise you to take certain precautions before taking a Spinraza injection. These include avoiding activities that could cause injury and with people who are sick.

After Taking Spinraza (Nusinersen)

1. Make sure to watch for any signs of an allergic reaction. These could include hives, swelling of the face, lips, tongue, or throat, or wheezing. In case of any allergic reaction, seek medical help immediately.

2. Monitor your body for any signs of infection, such as fever, chills, body aches, or a sore throat. If any of these symptoms occur, seek medical help promptly.

3. Stay hydrated by drinking plenty of fluids. This helps to flush out the medicine from your body.

4. Monitor your breathing and heart rate regularly.

5. Wear loose clothing to help reduce discomfort after the injection.

6. Avoid strenuous activities for at least 24 hours after the Spinraza injection.

7. Avoid contact with people who have recently had an infection.

8. Do not take medications that may interact with Spinraza without consulting your doctor.

9. Make sure to keep any follow-up appointments with your doctor.

10. Talk to your doctor about special instructions specific to your condition, such as dietary and lifestyle modifications.

How Spinraza Stops The Progression Of SMA?

Spinraza (nusinersen) is a medication used to treat spinal muscular atrophy (SMA). It increases the amount of the SMN2 protein, which helps control muscle function. It is the first approved treatment for SMA and is given as a one-time dose.

When Spinraza is injected into the fluid that surrounds the spinal cord, it binds to a specific receptor on the SMN2 gene. This binding causes the SMN2 gene to produce more of the SMN2 protein. The increased production of the SMN2 protein helps to stop the progression of SMA by allowing the muscles to function more efficiently. The increased levels of the SMN2 protein can also help to protect motor neurons from further damage. This protection can help to improve motor function and prevent further muscle weakness.

Spinraza is not a cure for SMA but can help slow the disease’s progression. With regular doses of Spinraza, people with SMA can expect to see improvement in their motor function and muscle strength. In some cases, people with SMA can even regain lost motor function. The effects of Spinraza are not immediate, and it can take a few months for the full effects to be seen. However, with regular doses, people with SMA can expect to see an improvement in their symptoms.

How Effective Is Spinraza In Treating SMA?

Spinraza (nusinersen) is a medication used to treat spinal muscular atrophy (SMA), a rare genetic disorder that causes progressive muscle weakness and paralysis. Spinraza works by increasing the amount of a protein called survival motor neuron (SMN) needed for healthy nerve cells to function correctly. By increasing the amount of SMN, Spinraza helps improve muscle strength and function in patients with SMA.

Spinraza is administered into the spine through a series of intrathecal injections. The first injection is given in a healthcare setting, and a healthcare professional can administer the following injections at home. In clinical trials, Spinraza improved motor milestones such as sitting, standing, and walking in people with SMA. In addition, Spinraza has been found to improve overall motor function and quality of life in people with SMA.

Spinraza is an effective treatment for SMA and is the only FDA-approved therapy proven to improve motor function in people with SMA. It is important to note that Spinraza is not a cure for SMA, but it does provide a way to manage the symptoms and slow the progression of the disease. Spinraza is safe and well-tolerated, but it is crucial to speak to a healthcare professional about the potential risks and benefits of Spinraza before starting treatment.

Additional Information On Spinraza

Spinraza is a biologic drug for treating spinal muscular atrophy (SMA). It is the first FDA-approved treatment for this condition and works by helping to increase the production of the SMN protein, which is essential for muscle function. The drug is given via an injection into the spinal canal and is taken every four months for the rest of a patient’s life.

Spinraza works by correcting the genetic defect that causes SMA. It uses a modified version of adeno-associated virus 9 (AAV9). This virus is modified to deliver the SMN gene directly to the cells, producing the SMN protein. This protein helps to protect and maintain the function of the nerves and muscles.

Spinraza is most effective in infants and young children with SMA, although it can also be prescribed for older children and adults. In clinical trials, Spinraza has been shown to improve muscle strength and function in children with SMA. It also decreases the number of respiratory events, such as difficulty breathing and chest infections, that can lead to hospitalization or even death.

The cost of Spinraza is high, but some programs can help cover the cost for those who qualify. It is crucial to talk to your doctor about any financial assistance programs that may be available.

For Which Rare Disease Is Spinraza Used As Medication Therapy?

Spinraza (nusinersen) is a medication used to treat spinal muscular atrophy (SMA). SMA is a rare, progressive genetic disorder that targets the motor neurons in the spinal cord, causing muscle weakness and, in many cases, death. Spinraza is the only FDA-approved treatment for SMA and is used to slow the progression of the disease and improve motor function. It is approved for use in children and adults with SMA Types 1, 2, 3, and 4. 

Spinraza is administered directly into the spinal cord fluid, known as the cerebrospinal fluid (CSF), using a lumbar puncture. During this procedure, a needle is inserted in the middle of two vertebrae in the lower back, and the medicine is injected directly into the CSF. The medicine works by increasing the production of a healthy SMN protein, which is essential for the functioning of motor neurons. This helps to slow the progression of the disease and improve motor function.

Spinraza is usually given as a series of four doses, followed by maintenance doses every four months. The loading doses are given at least 14 days apart and are followed by maintenance doses every four months. The treatment duration depends on the patient’s condition and response to the medication. 

Overall, Spinraza is used to treat spinal muscular atrophy, a rare, progressive genetic disorder affecting the spinal cord’s motor neurons. It is used to slow the progression of the disease and improve motor function and is usually given as a series of four loading doses, followed by maintenance doses that are given every four months.

History Of Spinraza

Spinraza (nusinersen) is a medication for treating spinal muscular atrophy (SMA). It is a first-of-its-kind drug designed to slow down the progression of the disease. In 2012, Ionis Pharmaceuticals, a biopharmaceutical company based in Carlsbad, California, first developed the drug. The development of the drug was based on the discovery of a mutation in the SMN2 gene responsible for the production of the Survival Motor Neuron (SMN) protein. The mutation was found to be the cause of SMA.

In 2014, the drug was tested in a clinical trial with over 120 patients. The trial showed that the drug effectively slowed the progression of SMA and improved motor function in many patients.

In December 2016, the drug was approved by the FDA (Food and Drug Administration) and became the first drug approved for SMA treatment. The approval was based on the clinical trial results, which showed that the drug was safe and effective.

Since then, Spinraza has been approved for use in over 50 countries worldwide. It is now the standard of care for treating SMA in many countries. The drug has been shown to improve motor function, increase survival, and improve the quality of life for SMA patients.

Clinical Trials For Spinraza

Spinraza (nusinersen) is a medication used to treat spinal muscular atrophy (SMA). Presently, it is approved for treating SMA types 1, 2, 3, and 4 in children 2 years of age and older and also adults.

The clinical trials for Spinraza began in 2013 and have since included more than 1,000 participants worldwide. The trials have included people with all types of SMA, including those with infantile-onset, childhood-onset, and adult-onset forms of the disease.

The first major clinical trial of Spinraza was a Phase 3 multicentre, double-blind, placebo-controlled trial called ENDEAR (Efficacy and Safety of Nusinersen in Patients with Spinal Muscular Atrophy). This trial included 126 patients aged 2 months to 60 years with SMA types 1, 2, 3, and 4 randomly assigned to receive either Spinraza or a placebo. The primary outcome was an improvement in the Hammersmith Functional Motor Scale Expanded (HFMSE) score, which measures motor function. The trial found that patients who received Spinraza significantly improved their HFMSE scores compared to those who received the placebo.

A second Phase 3 clinical trial, CHERISH (A Clinical Trial of Nusinersen in Pediatric and Adult Patients with Spinal Muscular Atrophy), included 166 patients aged 4 months to 60 years with SMA types 2, 3, and 4. This trial found that patients who received Spinraza experienced a significant improvement in the motor domain of the CHOP-INTEND (Children’s Hospital of Philadelphia Infant Test of Neuromuscular Disorders)score and a significant improvement in the HFMSE score compared to those who received the placebo.

The clinical trials for Spinraza also included open-label studies and extensions of the Phase 3 trials. The open-label studies included patients who had previously enrolled in the Phase 3 trials and were allowed to continue receiving Spinraza. The extension studies included patients who had completed the Phase 3 trials and were allowed to continue receiving Spinraza for a more extended period.

The clinical trials for Spinraza have shown that the drug effectively improves motor function in patients with SMA types 1, 2, 3, and 4. Now, the drug has been approved by the U.S. Food and Drug Administration (FDA). 

How To Cover The High Cost Of Spinraza (Nusinersen) In India?

Spinraza is a medication used to treat spinal muscular atrophy (SMA). It is a costly medication and is not available in India. In order to cover the cost of Spinraza in India, the patient’s family must first research to determine the best option for them. 

1. Look into local and national health insurance providers: India is home to several health insurance providers, both local and national. If a patient or family is covered under one of these plans, they can inquire whether Spinraza is covered. 

2. Apply for financial assistance: Several organizations assist those who can’t afford Spinraza. The patient or family should contact their local hospital or doctor to see what options are available. 

3. Look into private funding: Spinraza is often covered by private insurance companies. Patients and families should contact their private insurance companies to see if they can cover the costs of Spinraza. 

4. Look into crowdfunding: Crowdfunding is a great way to get the support needed to cover the cost of Spinraza. Patients and families can set up a crowdfunding page and ask for donations from family and friends. 

5. Seek out grants: Several organizations offer grants to those in need. Patients and families should contact their local hospital or doctor to see if they can assist. 

6. Look into government programs: There are several government programs that can assist those in need. Patients and families should contact their local government to see if any programs are available. 

These are some ways that patients and families can cover the cost of Spinraza in India. It is essential to do research and contact the necessary organizations to find the best financial option. 

You Can Try Medical Fundraising To Cover The Cost Of Spinraza In India!

Medical crowdfunding is an increasingly popular option for individuals unable to pay for medical treatments and procedures. It allows individuals to raise funds from family, friends, and the public to help cover the cost of medical treatments and procedures not covered under insurance or other financial sources. 

In India, medical crowdfunding has become an increasingly popular option for those who cannot afford the cost of expensive treatments such as Spinraza. Spinraza is a treatment used to treat spinal muscular atrophy (SMA), a rare and sometimes deadly genetic disorder. Treatment with Spinraza is costly and is not covered by most insurance companies in India. For many, the cost of Spinraza can be prohibitive. This is where medical fundraising comes in.

Medical crowdfunding allows individuals to raise money to cover the cost of treatments, such as Spinraza, not covered by insurance or other financial sources. Through an online crowdfunding platform like ImpactGuru, individuals can create a fundraising page to share their stories and explain their need for financial assistance. Individuals can accept donations from family, friends, and the general public through the platform. Medical crowdfunding is an excellent option for those who cannot afford the cost of Spinraza in India. It is an accessible and transparent way to raise funds for medical treatments and procedures. 

When you’re unsure how to get financial help for a medical cause and feel like you’ve reached a bottleneck, ImpactGuru is there for you. If you haven’t already started, create a fundraiser and begin your journey towards debt-free and healthy living.